Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Structure and Function of Platelets01:18

Structure and Function of Platelets

7.2K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
7.2K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

6.3K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.3K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

6.1K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A standardised approach to the pathological dissection and reporting of pelvic exenteration specimens: Recommendations from the UK Pelvic Exenteration Network (UKPEN).

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland·2026
Same author

Matching dynamically varying forces with multi-motor-unit muscle models: a simulation study.

Royal Society open science·2025
Same author

Genetic diversity and population structure of a rare flowering tree endemic to Appalachia, <i>Stewartia ovata</i>.

Ecology and evolution·2024
Same author

Author Correction: Large language models and agricultural extension services.

Nature food·2023
Same author

Large language models and agricultural extension services.

Nature food·2023
Same author

Impact of the COVID-19 pandemic on a post-mortem CT service for adult non-suspicious death.

Clinical radiology·2023

Related Experiment Video

Updated: May 5, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.9K

Inhibition of platelet function by recombinant soluble ecto-ADPase/CD39

R B Gayle1, C R Maliszewski, S D Gimpel

  • 1Immunex Corporation, Seattle, Washington 98101, USA. gayler@immunex.com

The Journal of Clinical Investigation
|June 13, 1998
PubMed
Summary

A novel soluble form of CD39, an enzyme that metabolizes platelet-activating molecules, was developed. This soluble CD39 effectively inhibits platelet aggregation and reactivity, showing potential as an antithrombotic therapy for cardiovascular diseases.

More Related Videos

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

1.3K
Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.7K

Related Experiment Videos

Last Updated: May 5, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.9K
Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

1.3K
Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.7K

Area of Science:

  • Cardiovascular Medicine
  • Biochemistry
  • Pharmacology

Background:

  • Platelet accumulation at vascular injury sites causes vessel occlusion, a significant challenge in cardiovascular medicine.
  • Endothelial cell CD39 metabolizes ATP and ADP, crucial for inhibiting platelet recruitment.

Purpose of the Study:

  • To design and characterize a recombinant soluble form of human CD39 as a novel antithrombotic agent.
  • To evaluate the therapeutic potential of soluble CD39 in inhibiting platelet-mediated thrombosis.

Main Methods:

  • Designed and isolated recombinant soluble human CD39 from transfected cell lines (COS-1 and CHO).
  • Purified soluble CD39 using anti-CD39 immunoaffinity chromatography.
  • Assessed ATPase and ADPase activities, inhibition of ADP- and collagen-induced platelet aggregation, and in vivo pharmacokinetics in mice.

Main Results:

  • Purified soluble CD39 demonstrated significant ATPase and ADPase activities.
  • Soluble CD39 effectively blocked ADP-induced platelet aggregation and inhibited collagen-induced platelet reactivity in vitro.
  • Intravenously administered soluble CD39 exhibited a long half-life (nearly 2 days) in mice, indicating sustained activity.

Conclusions:

  • Recombinant soluble CD39 is a potent inhibitor of platelet aggregation and reactivity.
  • Soluble CD39 represents a promising therapeutic candidate for treating platelet-mediated thrombotic disorders.